Literature DB >> 9558290

Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation.

D H Crawford1, E C Jazwinska, L M Cullen, L W Powell.   

Abstract

BACKGROUND & AIMS: In the absence of a genetic test, diagnostic criteria for hereditary hemochromatosis have been imprecise. The identification of the HFE gene and the C282Y mutation allow definition of expression of this disease and reassessment of diagnostic criteria. The aim of this study was to analyze the concordance between the genetic diagnosis and the previous clinical diagnosis in families with hemochromatosis.
METHODS: Three hundred subjects were tested for the C282Y mutation and were grouped as homozygous, heterozygous, or homozygous normal.
RESULTS: All adults previously diagnosed as homozygous or heterozygous for HLA-linked hereditary hemochromatosis carried at least one C282Y mutation. Two adolescents, previously thought to be homozygous, had no C282Y mutation. Of 127 subjects homozygous for the mutation, 105 met criteria for diagnosis. Iron overload was not expressed in 6.7% of homozygous men and 32.7% of homozygous women. The iron indices in 8 of 171 subjects heterozygous for the C282Y mutation were within the range previously regarded as indicative of homozygosity. Seven of these 8 carried the H63D mutation.
CONCLUSIONS: In Australia, 17.3% of subjects homozygous for the C282Y mutation do not express iron overload to meet current diagnostic criteria of hemochromatosis. In subjects heterozygous for the mutation, 4.8% have iron overload in the range previously diagnosed as homozygous. Nonexpression is common, particularly in women.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9558290     DOI: 10.1016/s0016-5085(98)70320-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

Review 1.  Controversy in primary care: Should asymptomatic haemochromatosis be treated?

Authors:  C J Seamark; M Hutchinson
Journal:  BMJ       Date:  2000-05-13

2.  Should we genetically test everyone for haemochromatosis?

Authors:  K Allen; R Williamson
Journal:  J Med Ethics       Date:  1999-04       Impact factor: 2.903

Review 3.  How to identify the genetic basis of gastrointestinal and liver diseases?

Authors:  P Ferenci
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 4.  A diagnostic approach to hemochromatosis.

Authors:  Anthony S Tavill; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-08       Impact factor: 3.522

5.  Iron overload and heart fibrosis in mice deficient for both beta2-microglobulin and Rag1.

Authors:  M M Santos; M de Sousa; L H Rademakers; H Clevers; J J Marx; M W Schilham
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

6.  Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients.

Authors:  C A McCune; D Ravine; K Carter; H A Jackson; D Hutton; J Hedderich; M Krawczak; M Worwood
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

7.  Clinical penetrance of C282Y homozygous HFE haemochromatosis.

Authors:  Enrico Rossi; Gary P Jeffrey
Journal:  Clin Biochem Rev       Date:  2004-08

8.  The significance of haemochromatosis gene mutations in the general population: implications for screening.

Authors:  M J Burt; P M George; J D Upton; J A Collett; C M Frampton; T M Chapman; T A Walmsley; B A Chapman
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

9.  Mutations in the hereditary haemochromatosis gene HFE in professional endurance athletes.

Authors:  J L Chicharro; J Hoyos; F Gómez-Gallego; J G Villa; F Bandrés; P Celaya; F Jiménez; J M Alonso; A Córdova; A Lucia
Journal:  Br J Sports Med       Date:  2004-08       Impact factor: 13.800

Review 10.  Screening for hemochromatosis: patients with liver disease, families, and populations.

Authors:  Sumedha P Galhenage; Charlie H Viiala; John K Olynyk
Journal:  Curr Gastroenterol Rep       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.